Pyxis Oncology, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
321 HARRISON AVENUE, BOSTON, MA, 02118
Mailing Address
321 HARRISON AVENUE, BOSTON, MA, 02118
Phone
(617) 221-9059
Fiscal Year End
1231
EIN
831160910
Financial Overview
FY2025
$-1.28
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 23, 2026 | View on SEC |
Annual Reports
10-K
March 23, 2026
- Develops novel antibody-drug conjugates (ADCs) and immunotherapies for difficult cancers.
- Operates as an early-stage, 'smaller reporting company' and 'emerging growth company', allowing for fewer reporting rules.
Material Events
8-K
Leadership Change
February 6, 2026
High Impact
- Interim CEO Tom Civik has a strong track record, including guiding Five Prime Therapeutics to acquisition by Amgen.
- Civik's compensation is heavily incentivized for successful financing or strategic transactions, signaling the Board's immediate priority.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.